Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02204072
Recruitment Status : Active, not recruiting
First Posted : July 30, 2014
Last Update Posted : December 4, 2019
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate resistant prostate cancer (CRPC) patients that have previously been treated and failed on docetaxel and abiraterone treatments. Initially, a tolerability and safety phase (phase Ib escalation) will be performed to confirm the maximum tolerated dose (MTD), or recommended doses of both BI 836845 and enzalutamide that can be taken together.

Once the MTD, or recommended phase II dose, have been determined an expansion cohort will also be explored (phase Ib expansion) in CRPC patients already taking enzalutamide and have a rise in prostate serum antigen (PSA) levels. Patients may not have received prior docetaxel or abiraterone. Patients in this cohort will receive the MTD, or recommended phase II dose, of BI 836845 and enzalutamide determined in the phase Ib escalation phase.

The randomised trial (phase II) will be an open label, parallel group study design in a 1:1 ratio to which patients will receive either BI 836845 plus enzalutamide (Arm A) at the MTD/recommended doses, or enzalutamide alone (Arm B).

In all parts of the trial safety, anti-tumour activity will be assessed, in addition to circulating tumour cells (CTC), prostate serum antigen (PSA) response and progression, and determination of Overall Survival (OS).


Condition or disease Intervention/treatment Phase
Prostatic Neoplasms, Castration-Resistant Drug: BI 836845 Drug: Enzalutamide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 117 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone
Actual Study Start Date : November 11, 2014
Actual Primary Completion Date : October 18, 2019
Estimated Study Completion Date : December 27, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: BI 836845 & Enzalutamide Drug: BI 836845
Drug: Enzalutamide
Active Comparator: Enzalutamide Drug: Enzalutamide



Primary Outcome Measures :
  1. Number of patients with dose limiting toxicities (phase Ib escalation) [ Time Frame: 6 months ]
  2. Maximum tolerated dose (phase Ib escalation) [ Time Frame: 6 months ]
  3. Prostate Surface Antigen (PSA) response - defined as a decline in PSA value >50% (which is confirmed by a second value 3 to 4 weeks apart) (phase Ib expansion) [ Time Frame: Up to 3 years ]
  4. Radiological Progression free survival - time from randomisation to disease progression based on investigator assessment in bone, or soft tissue, or death (phase II) [ Time Frame: Up to 3 years ]

Secondary Outcome Measures :
  1. Overall survival - defined as the time from randomisation to death from any cause (phase II) [ Time Frame: Up to 3 years ]
  2. Time to prostate serum antigen (PSA) progression - defined as the date that a 25% or greater increase in PSA, and an absolute increase of 2 ng/mL or more from the nadir, is documented, which is confirmed by a second value 3 or more weeks later (phase II) [ Time Frame: Up to 3 years ]
  3. Maximum decline in PSA - compared to baseline that occurs at any point after treatment start (phase II) [ Time Frame: Up to 3 years ]
  4. Percentage change in PSA - from baseline to week 12 of treatment (phase II) [ Time Frame: Up to 3 years ]
  5. CTC response-CTC reduction compared to baseline for at least one time point after treatment start assessed by maximum change in CTC counts compared to baseline that occurs at any point after treatment start (phase II) [ Time Frame: Up to 3 years ]
  6. Radiological progression free survival - defined as time from start of treatment to disease progression based on investigator assessment in bone based on PCWG2 or soft tissue based on modified RECIST 1.1 where applicable, or death (phase Ib expansion) [ Time Frame: Up to 3 years ]
  7. Changes in CTC response - CTC reduction compared to baseline for at least one time point after treatment start assessed by CTC decline from, equal to, or more than, 5 to <5 cells per 7.5ml blood (phase II) [ Time Frame: Up to 3 years ]
  8. Changes in circulating tumour cells (CTC) response - CTC reduction compared to baseline for at least one time point after treatment defined as CTC decline from, equal to, or more than, 5 to <5 cells per 7.5ml blood (phase Ib expansion) [ Time Frame: Up to 3 years ]
  9. PSA response - defined as a decline in PSA value >50%, which is confirmed by a second value 3 to 4 weeks apart (phase II) [ Time Frame: Up to 3 years ]
  10. Radiological progression free survival - defined as time from randomisation to disease progression based on central review in bone based on PCWG2 or soft tissue based on modified RECIST 1.1 where applicable, or death (phase II) [ Time Frame: Up to 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • The patient has histologically, or cytologically, confirmed adenocarcinoma of the prostate.
  • Male patient aged, equal to, or more than,18 years old.
  • Patients with radiographic evidence of metastatic prostate cancer (stage M1 or D2). Distant metastases evaluable by radionuclide bone scan, CT scan, or MRI within 28 days before the start of study treatment.
  • Patients with a prostate serum antigen (PSA), equal to, or more than, 5 ng/mL.
  • Patients with prior surgical or chemical castration with a serum testosterone of <50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the patient must be willing to continue the use of LHRH agonists during protocol treatment.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1 or 2.
  • Cardiac left ventricular function with resting ejection fraction >50% as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA).
  • Absolute neutrophil count (ANC) >=1500/microlitre (uL).
  • Haemoglobin >=9 g/dL.
  • Platelets >=100,000/uL.
  • Bilirubin <= 1.5 times the upper limit of normal (ULN).
  • Aspartate transaminase (AST) and alanine transaminase (ALT) <= 2.5 times the ULN(or <= 5 times the ULN if liver metastases are present).
  • Creatinine <= 1.5 x ULN.
  • International normalized ratio (INR) </= 2 and a partial thromboplastin time (PTT) </= 5 seconds above the ULN (unless on oral anticoagulant therapy). Patients receiving full dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (except warfarin or coumarin-like anticoagulants, which are not permitted).
  • Fasting plasma glucose < 8.9 mmol/L (< 160 mg/dL) and HbA1c < 8.0%.

Inclusion criteria only for patients entering phase Ib escalation and phase II:

  • Patients who have disease progression during, or after, receiving docetaxel and have had at least 12 weeks of treatment and in the opinion of the investigator are unlikely to derive significant benefit from additional docetaxel-based therapy, or were intolerant to therapy with this agent.
  • Patients who have disease progression during, or after, receiving abiraterone treatment in any setting.
  • Patients must have progressive disease defined as at least one of the following:

    1. Progressive measurable disease: using conventional solid tumour criteria RECIST 1.1.
    2. Bone scan progression: at least two new lesions on bone scan, plus a rising PSA as described in (c) below.
    3. Increasing PSA level: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2.

Inclusion criterion only for patients entering phase Ib expansion cohort:

  • Patients must be receiving continuous enzalutamide treatment and show a rise in PSA level: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2.
  • Archive tumour tissue is available prior to recruitment for pharmacogenomic tests

Exclusion criteria:

  • Prior therapy with agents targeting Insulin Growth Factor (IGF) and/or Insulin Growth Factor Receptor (IGFR) pathway.
  • Patients that have been treated with any of the following within 4 weeks of starting trial treatment: chemotherapy, immunotherapy, biological therapies, molecular targeted, hormone therapy (except LHRH agonists and LHRH antagonists), radiotherapy (except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within 2 weeks prior to study treatment).
  • Use of any investigational drug within 4 weeks before start of trial treatment or concomitantly with this trial.
  • Patients that have been treated with strong cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) inhibitors, CYP2C8 inducers, within 2 weeks of starting the trial treatment.
  • Fridericia´s Corrected QT interval (QTcF) prolongation > 450 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome). The QTcF will be calculated as the mean of the 3 ECGs taken at screening.
  • Patients with small cell or neuroendocrine tumours.
  • Patients with known or suspected leptomeningeal metastases.
  • Uncontrolled or poorly controlled hypertension.
  • Known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.
  • Patients with epilepsy, seizures, or predisposing factors for seizure as judged by the investigator.
  • Patients unable to comply with the protocol as judged by the investigator.
  • Active alcohol or active drug abuse as judged by the investigator.
  • A history of allergy to human monoclonal antibodies.
  • Patients who are sexually active and unwilling to use a medically acceptable method of contraception, e.g. condom plus spermicide use for participating males, plus another form of birth control such as implants, injectables, combined oral contraceptives, intrauterine devices for female partners, during the trial and for at least three months after end of active therapy. Men unwilling to agree to not donate sperm while on trial drug and up to 6 months following the last dose of trial drug.
  • Previous or concomitant malignancies at any other site with the exception of the following:

    • benign basal cell carcinoma
    • benign low grade transitional cell carcinoma of the bladder
    • other effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured
  • Only for patients entering phase Ib dose escalation and phase II cohorts:
  • Patients who have received more than 2 prior non-docetaxel containing cytotoxic chemotherapy regimens for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • Patients who have received a taxane based treatment or abiraterone, within 4 weeks before start of study treatment.
  • Patients that have received prior enzalutamide in any setting will not be eligible.

Exclusion criterion only for patients entering phase Ib expansion cohort:

- Patients that have received prior taxane-based chemotherapy or abiraterone in any setting will not be eligible for the expansion cohort.

Additional exclusion criterion for patients undergoing tumour biopsy:

  • For patients that are to undergo the tumour biopsy, a history of a hereditary bleeding disorder, or clinically relevant major bleeding event in the past 6 months, as judged by the investigator.
  • Further exclusion criteria apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02204072


Locations
Layout table for location information
United States, Michigan
Kamanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, New York
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York, United States, 10065
United States, Oregon
Oregon Health and Sciences University
Portland, Oregon, United States, 97239
Hong Kong
Prince of Wales Hospital
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Netherlands
Erasmus MC - Daniel den Hoed
Rotterdam, Netherlands, 3075 EA
Tweesteden Ziekenhuis, locatie Tilburg
Tilburg, Netherlands, 5042 AD
Singapore
National Cancer Centre
Singapore, Singapore, 169610
OncoCare Cancer Centre
Singapore, Singapore, 258499
Johns Hopkins Singapore International Medical Center
Singapore, Singapore, 308433
Spain
Hospital Vall d'Hebron
Barcelona, Spain, 08035
Hospital Clínic de Barcelona
Barcelona, Spain, 08036
Hospital Santa Creu i Sant Pau
Barcelona, Spain, 08041
Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain, 08908
Hospital General Universitario Gregorio Marañón
Madrid, Spain, 28007
Hospital Ramón y Cajal
Madrid, Spain, 28034
Instituto Valenciano de Oncología
Valencia, Spain, 46009
Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan, 40705
National Taiwan University Hospital
Taipei, Taiwan, 100
Taipe Veterans General Hospital
Taipei, Taiwan, 11217
United Kingdom
Clatterbridge Cancer Centre
Bebington, Wirral, United Kingdom, CH63 4JY
Velindre Cancer Centre
Cardiff, United Kingdom, CF14 2TL
The Christie Hospital
Manchester, United Kingdom, M20 4BX
Churchill Hospital
Oxford, United Kingdom, OX3 7LE
The Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02204072     History of Changes
Other Study ID Numbers: 1280.8
2013-004011-41 ( EudraCT Number )
First Posted: July 30, 2014    Key Record Dates
Last Update Posted: December 4, 2019
Last Verified: December 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases